Understanding how specific immune cells interact with gut bacteria
Official title: Investigating a RORgt-expressing antigen presenting cell required for peripheral Treg responses to gut microbiota
Funded at New York University School of Medicine · NIH-10997014 · Data updated 2026-11-12
This study is looking at a special kind of immune cell in the gut that helps keep things balanced between fighting off germs and preventing inflammation, which could lead to better treatments for people with inflammatory bowel diseases (IBD).
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | November 1, 2024 |
| Project end | October 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $74,284 |
| NIH project number | 1F32AI181496-01A1 |
| Project ID | NIH-10997014 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with inflammatory bowel diseases or those experiencing gut-related immune issues.
✕Less likely to help
Patients with non-gut related autoimmune diseases or those without any gastrointestinal symptoms may not benefit from this research.
What this research studies
This research investigates a unique type of immune cell in the gut that expresses a protein called RORgt, which plays a crucial role in how our immune system responds to the bacteria living in our intestines. By studying these RORgt-expressing antigen presenting cells (APCs), the research aims to uncover how they help maintain a balance between tolerance and inflammation in the gut. This could lead to new strategies for treating inflammatory bowel diseases (IBD) by enhancing our understanding of how these immune cells function and interact with gut microbiota.
Why it matters
Potential benefit: If successful, this research could lead to new treatments for inflammatory bowel diseases, improving the quality of life for patients suffering from these conditions.
How similar studies have gone: Previous research has shown promise in understanding immune responses to gut microbiota, but the specific role of RORgt-expressing APCs is still being explored, making this a novel investigation.
Where this research is happening
-
New York University School of Medicine
New York, United States Active
Researchers
- Principal investigator: Chen, Francis M — New York University School of Medicine
- Study coordinator: Chen, Francis M
Related research
Other NIH-funded projects on the same topics.
-
Gut microbiome and Parkinson's disease: how gut bugs relate to symptoms and progression
A multi-year study will look at gut bacteria and related markers in people with Parkinson’s disease to understand how the gut-brain connection may influence symptoms and progression.
-
Gut-Brain Axis in Parkinson’s Disease: biomarkers and procedures to track progression
A patient-focused program to study how gut health and the brain interact in Parkinson’s disease using biomarkers and clinical procedures.
-
Vitamin D, gut bacteria and dementia risk in older adults with HIV
This work will look at whether low vitamin D and changes in gut bacteria are linked to higher dementia risk in older adults living with chronic HIV and similar community members.
-
Gut bacteria and lung immune cells shape viral lung infections
A study explores how gut microbes affect lung immune cells and severity of respiratory viral infections to identify potential ways to reduce illness.
-
Gut bacteria and Tuft-2 cells linked to early colorectal cancer risk in young Black Americans
This grant aims to understand how gut microbes and Tuft-2 cells may predict aggressive colon adenomas in young Black adults who develop colorectal cancer.
-
Gut bacteria, HIV, and alcohol: how microbes affect gut health in people with HIV
This NIH grant studies how alcohol use and HIV together affect the gut’s bacteria and barrier, exploring a possible way to reduce gut inflammation in people living with HIV.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.